Profil bibliographique

Doreen Fernsler

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

26Publications signalées

464Citations signalées

1Affiliations récentes

Les institutions déclarées

Merck & Co., Inc., Rahway, NJ, USA (United States)

Les domaines associés

Pneumonia and Respiratory InfectionsRespiratory viral infections researchHepatitis C virus researchInfluenza Virus Research StudiesLiver Disease Diagnosis and Treatment

Les publications récentes

Accès ouvert 2025 article OpenAlex

A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8

Paul T. Scott, Jayani Pathirana, Akira Kato, Richard Tytus et autres

us, jp, ca, cl, nz, kr, pl, au (code pays fourni par la source)

2 citations Clinical Infectious Diseases

2025 article OpenAlex

Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial

Jayani Pathirana, Moti Ramgopal, Charlotte Martin, Johannes Lombaard et autres

ch, us, be, cl, fr, th, il, de (code pays fourni par la source)

3 citations The Lancet HIV

2025 article OpenAlex

A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older

Tosin Omole, Aaron S. Weinberg, Masoud Azizad, David Greenberg et autres

us, il (code pays fourni par la source)

3 citations Vaccine

2025 article OpenAlex

A phase 3, randomized trial to evaluate lot-to-lot consistency of V116, an adult-specific pneumococcal conjugate vaccine (STRIDE-4)

Paul T. Scott, Benita Ukkonen, Yoseph Caraco, Silvia Narejos Pérez et autres

us, fi, il, es (code pays fourni par la source)

1 citation Med

Accès ouvert 2025 article OpenAlex

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10)

Veronika Jotterand, Vinita Jagannath, Juan D. Vélez, Arna Letica et autres

ch, gb, co, nz, es, il, de, kr, tr, us (code pays fourni par la source)

5 citations Vaccines

Accès ouvert 2025 article OpenAlex

P-45. A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Investigational Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age with Increased Risk for Pneumococcal Disease

Paul T. Scott, Jayani Pathirana, Akira Kato, Richard Tytus et autres

us, jp, ca, cl, kr, pl, au (code pays fourni par la source)

0 citations Open Forum Infectious Diseases

Accès ouvert 2024 article OpenAlex

A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)

Paul T. Scott, Miwa Haranaka, Jung‐Hyun Choi, Helen Stacey et autres

us, jp, kr, ca, il (code pays fourni par la source)

34 citations Clinical Infectious Diseases

2024 article OpenAlex

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx, Enrique Pelayo et autres

us, cl, pr, se, kr (code pays fourni par la source)

59 citations The Lancet Infectious Diseases

Accès ouvert 2024 article OpenAlex

P21 A Phase 3 randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability and immunogenicity of a 21-valent PCV, V116, in pneumococcal vaccine-naive adults (STRIDE-3)

Christopher Bruno, Erik Buntinx, Enrique Pelayo, Jackie M Kamerbeek et autres

us, nz, cl, pr, se, kr, il (code pays fourni par la source)

0 citations JAC-Antimicrobial Resistance

Accès ouvert 2023 article OpenAlex

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)

Thomas J. Sferra, Tomáš Merta, Michael Neely, Cláudia Murta de Oliveira et autres

us, cz, es, gb (code pays fourni par la source)

12 citations Journal of the Pediatric Infectious Diseases Society

Accès ouvert 2023 article OpenAlex

P09 A Phase 2, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (V116) in adults ≥50 years

Tosin Omole, José Cardona, Neil J. Fraser, Sandra Pagnussat et autres

us (code pays fourni par la source)

0 citations JAC-Antimicrobial Resistance

Accès ouvert 2023 article OpenAlex

P08 A Phase 1, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine (PCV) (V116) in adults

Heather Platt, Doreen Fernsler, Nancy Gallagher, Aditi Sapre et autres

us (code pays fourni par la source)

0 citations JAC-Antimicrobial Resistance

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.